RJS Biologics is Drug Delivery in United States that focus on cancer treatments business. Founded in 2009. They cover business area such as developer, novel cancer therapeutic, therapy, cancer treatment, beneficial therapeutic, patient, affinity tag, therapeutic compound, cancer cell, a pipeline, conjugate anti-cancer compound, payload, clinically-relevant target, kinase inhibitor, cell cycle inhibitor, proper treatment, any side effect.
2009
( 15 years old in 2024 )
Cancer Treatments
-
819 North 49th Street
Suite 307
Seattle, WA 98103
United States
Private
developernovel cancer therapeutictherapycancer treatmentbeneficial therapeuticpatientaffinity tagtherapeutic compoundcancer cella pipelineconjugate anti-cancer compoundpayloadclinically-relevant targetkinase inhibitorcell cycle inhibitorproper treatmentany side effect
* We use standard office opening hours in near RJS Biologics's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
RJS Biologics is Drug Delivery business from United States that founded in 2009 (15 years old in 2024), RJS Biologics business is focusing on Cancer Treatments.
RJS Biologics headquarter office and corporate office address is located in 819 North 49th Street Suite 307 Seattle, WA 98103 United States.
RJS Biologics was founded in United States.
In 2024, RJS Biologics is currently focus on cancer treatments sector.
Above is snippet of Google Trends for "cancer treatments" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with RJS Biologics, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
